Every 424B that LifeStance Health Group, Inc. (LFST) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow LFST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFST filings page.
LifeStance Health Group, Inc. (LFST) has filed a prospectus supplement for a secondary offering of 22,250,000 shares of common stock by existing selling stockholders. LifeStance is not issuing new shares and will not receive any proceeds from the stockholders’ sales.
Contingent on the closing of this offering, LifeStance intends to repurchase 2,000,000 of the offered shares from the underwriter for approximately $24.58 million, funded with cash on hand under its existing share repurchase program. The shares purchased in the repurchase will be retired and will no longer be outstanding. LFST common stock trades on Nasdaq under the symbol LFST.
LifeStance Health Group, Inc. (LFST) has filed a preliminary prospectus supplement for a secondary offering of 22,250,000 shares of common stock, all to be sold by existing selling stockholders. LifeStance is not issuing new shares and will not receive proceeds from these sales; the selling stockholders will receive the offering proceeds.
Conditioned on the completion of the offering, LifeStance intends to repurchase 2,000,000 shares from the underwriter using cash on hand under its existing share repurchase program and then retire those shares, which will no longer be outstanding. This repurchase is contingent on the offering’s closing, while the offering itself is not conditioned on the repurchase. Shares outstanding were 382,154,147 as of September 1, 2026, and LFST last traded at $12.80 on September 8, 2026.
LifeStance Health Group, Inc. is offering for resale 35,000,000 shares of common stock by selling stockholders; the Company is not selling any shares hereunder and will receive no proceeds from those sales. Subject to the closing of the offering, the Company intends to purchase 6,000,000 shares from the underwriter at the public offering price and retire them. The repurchase is contingent on the offering closing. Shares outstanding were 387,834,432 as of April 29, 2026. The underwriter is J.P. Morgan, the public offering price is $8.15 per share and the underwriting discount is $0.13 per share. The underwriter expects to deliver the shares on or about May 12, 2026.
35,000,000 shares of common stock are being registered for resale by identified selling stockholders of LifeStance Health Group, Inc. The Company is not selling any shares and will not receive proceeds from the selling stockholders' sales.
Subject to the offering closing, LifeStance intends to purchase 6,000,000 of the offered shares from the underwriter at the same per-share price paid by the underwriter and retire those repurchased shares. Shares outstanding were 387,834,432 as of April 29, 2026. The prospectus supplement states the Company estimates offering expenses of approximately $500,000 and quotes a last reported Nasdaq sale price of $7.36 on May 6, 2026.
LifeStance Health Group, Inc. is registering 25,000,000 shares of its common stock for resale by selling stockholders under a prospectus supplement.
The offering is a resale by selling stockholders; the Company will receive no proceeds from these sales and intends, subject to the offering closing, to repurchase 7,000,000 shares at the underwriter purchase price and retire those repurchased shares. Shares outstanding used for disclosure were 389,783,210 shares as of February 17, 2026. The underwriter agreed to purchase the shares from the selling stockholders at $7.01 per share, and delivery is expected on or about March 2, 2026.
LifeStance Health Group, Inc. is registering 25,000,000 shares of common stock for resale by selling stockholders under a preliminary prospectus supplement dated February 25, 2026.
The Company will not receive proceeds from these sales; it intends, subject to the offering closing, to repurchase 7,000,000 shares of the shares being sold at the same per-share price paid to the selling stockholders and retire those repurchased shares. Shares outstanding were 389,783,210 as of February 17, 2026. The filing lists a Nasdaq last sale price of $7.14 per share on February 24, 2026.